PD-0200347

a ligand reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Boileau, Christelle: 1 article (02/2005)
2.	Boily, Martin: 1 article (02/2005)
3.	Brunet, Julie: 1 article (02/2005)
4.	El-Kattan, Ayman: 1 article (02/2005)
5.	Flory, Craig: 1 article (02/2005)
6.	Martel-Pelletier, Johanne: 1 article (02/2005)
7.	Pelletier, Jean-Pierre: 1 article (02/2005)
8.	Schrier, Denis: 1 article (02/2005)
9.	Tardif, Ginette: 1 article (02/2005)

Related Diseases

1.

Osteoarthritis 02/01/2005 - "To examine the in vivo effects of PD-0200347, an alpha(2)delta ligand of voltage-activated Ca(2+) channels and a compound chemically related to pregabalin and gabapentin, on the development of cartilage structural changes in an experimental dog model of osteoarthritis (OA). " 02/01/2005 - "Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes."

Related Drugs and Biologics

1.	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
2.	Metalloproteases (Metalloproteinases)
3.	Ligands
4.	Gabapentin (Neurontin)
5.	Pregabalin (Lyrica)